Support for anti-LAG-3 and APC-activator combos
Data presented at the European Society for Medical Oncology (ESMO) congress by third parties has positive implications for Prima Biomed’s LAG3...
69 Views
Support for anti-LAG-3 and APC-activator combos
Data presented at the European Society for Medical Oncology (ESMO) congress by third parties has positive implications for Prima Biomed’s LAG3...
63 Views
Preliminary LAG-3 combo data in breast cancer
Preliminary efficacy data, which Prima BioMed presented at ASCO from the 15-patient, safety run-in phase of its AIPAC study, showed sustained...
148 Views
Initial LAG-3 combo data presented
Prima BioMed has presented encouraging early signs of efficacy from the TACTI-mel trial of IMP321 in combination with Keytruda, with one of the six...
67 Views
Initial LAG-3 combo data presented
Prima BioMed has presented encouraging early signs of efficacy from the TACTI-mel trial of IMP321 in combination with Keytruda, with one of the six...
55 Views